NASDAQ
Passage Bio, Inc. (PASG)
♥ 488 Thanks from members
Passage Bio, Inc. (PASG) faces intense market skepticism and extreme cash runway pressures, evidenced by its planned all-stock merger with Remix Therapeutics, aggressive workforce reductions, and winding down of AAV gene therapy programs despite narrow Q2 earnings beats.